IMPEDIMED LIMITED (IPD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IPD - IMPEDIMED LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.01
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.16

05 Jun
2023

0.020

OPEN

$0.15

14.29%

HIGH

$0.16

8,124,563

LOW

$0.15

TARGET
$0.19 18.8% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . HLA . IDX . IME . IMR . LDX . MEB . MX1 . NAN . ONE . OVN . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
IPD: 1
Title FY21
Actual		 FY22
Actual		 FY23
Forecast		 FY24
Forecast
EPS (cps) xxx - 1.2 - 1.1 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201720182019202020212022
EPS Basic xxxxxxxxxxxxxxx-1.2
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx10.6 M
Book Value Per Share xxxxxxxxxxxxxxx2.9
Net Operating Cash Flow xxxxxxxxxxxxxxx-15.7 M
Net Profit Margin xxxxxxxxxxxxxxx-188.09 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201720182019202020212022
Return on Capital Employed xxxxxxxxxxxxxxx-51.92 %
Return on Invested Capital xxxxxxxxxxxxxxx-51.81 %
Return on Assets xxxxxxxxxxxxxxx-42.78 %
Return on Equity xxxxxxxxxxxxxxx-51.92 %
Return on Total Capital xxxxxxxxxxxxxxx-54.99 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-15.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201720182019202020212022
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx-
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx3 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx41 M
Price To Book Value xxxxxxxxxxxxxxx2.12

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201720182019202020212022
Capex xxxxxxxxxxxxxxx5.2 M
Capex % of Sales xxxxxxxxxxxxxxx49.41 %
Cost of Goods Sold xxxxxxxxxxxxxxx24 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx8 M
Research & Development xxxxxxxxxxxxxxx1 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

17/05/2023

1

Speculative Buy

$0.19

18.75%

Morgans suggests an announcement (timing uncertain) of a medical policy determination from a larger insurer will be the next key catalyst for ImpediMed.

In addition, following the inclusion of the company's BIS technology in the National Comprehensive Cancer Network (NCCN) guidelines, the broker is focusing upon the rate of growth in the installed base. 

An update to Morgans financial model results in a 19c target, up from 18c. Speculative Buy.

FORECAST
Morgans forecasts a full year FY23 dividend of 0.00 cents and EPS of minus -1.10 cents.
Morgans forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -0.60 cents.
Access Stockbroker Research History >

IPD STOCK CHART

FNArena News on IPD

1
Australian Broker Call *Extra* Edition – Jun 01, 2023

Jun 01 2023 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – May 12, 2023

May 12 2023 - Daily Market Reports
3
Dr Boreham’s Crucible: Impedimed

May 08 2023 - Small Caps
4
Australian Broker Call *Extra* Edition – Apr 20, 2023

Apr 20 2023 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Apr 11, 2023

Apr 11 2023 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Fisher & Paykel Healthcare: Lower Margin, Higher Spending

May 30 2023 - Australia
2
Dr Boreham’s Crucible: Impedimed

May 08 2023 - Small Caps
3
Treasure Chest: ResMed’s Benevolent Monopoly

May 01 2023 - Treasure Chest
4
Dr Boreham’s Crucible: Volpara Health Technologies

Apr 26 2023 - Small Caps
5
Dr Boreham’s Crucible: SDI

Mar 16 2023 - Small Caps
6
Dr Boreham’s Crucible: Cochlear

Mar 03 2023 - Australia
7
Dr Boreham’s Crucible: Imagion Biosystems

Feb 13 2023 - Small Caps
8
ResMed: Philips Remains The Big Unknown

Jan 31 2023 - Australia
9
Nanosonics Outlook Remains Clouded

Jan 24 2023 - Small Caps
10
Nanosonics Recovers On Less Negative Sentiment

Nov 29 2022 - Small Caps